People in the News

Premium

Vance Vanier will take over the president and CEO positions at Navigenics.

Vanier started at Navigenics in 2008 and was serving as chief medical officer of the consumer genomics firm. Before joining Navigenics, he was a partner at Mohr Davidow Ventures. He also is a clinical faculty member at Stanford University Medical Center.


Complete Genomics said recently that Aaron Solomon joined the firm as vice president of business development.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

While gene therapies may have high price tags, they could be cheaper than the cost of managing disease, according to MIT's Technology Review.

Researchers are looking for markers that indicate which cancer patients may respond to immunotherapies, the Associated Press writes.

In Nature this week: paternal age associated with de novo mutations in children, and more.

Nature News writes that researchers are still wrangling over the role of the p-value.